{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:29:18Z","timestamp":1785558558845,"version":"3.56.0"},"reference-count":80,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>Obesity is a growing global health challenge and a significant contributor to the rising prevalence of heart failure (HF), affecting both HF with preserved and reduced ejection fraction. While obesity increases HF incidence through haemodynamic stress, neurohormonal activation, metabolic dysfunction and systemic inflammation, the so-called \u2018obesity paradox\u2019 complicates our understanding of prognosis in established HF. This review examines the complex bidirectional relationship between obesity and HF, summarising evidence for the effects of intentional weight loss on cardiac structure, function and clinical outcomes. Bariatric surgery provides consistent benefits across HF phenotypes, while dietary and pharmacological interventions, particularly glucagon-like peptide-1 (GLP-1) receptor agonists, show promise for cardiometabolic improvement. Emerging evidence also supports structured exercise and rehabilitation programmes. However, gaps remain regarding the long-term efficacy of interventions and the additive benefit of GLP-1 receptor agonists with sodium\u2013glucose cotransporter-2 inhibitors. Understanding and targeting obesity in HF is essential for the improvement in morbidity and mortality in this high-risk population.<\/jats:p>","DOI":"10.15420\/ecr.2025.37","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T17:41:00Z","timestamp":1766338860000},"source":"Crossref","is-referenced-by-count":3,"title":["Targeting Obesity for Heart Failure"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8521-2113","authenticated-orcid":false,"given":"Emily","family":"Morris","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/052gg0110","id-type":"ROR","asserted-by":"publisher"}],"name":"Prifysgol Rhydychen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1295-7769","authenticated-orcid":false,"given":"Oliver","family":"Rider","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/052gg0110","id-type":"ROR","asserted-by":"publisher"}],"name":"Prifysgol Rhydychen"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Khan MS, Shahid I, Bennis A, et al. Global epidemiology of heart failure. Nat Rev Cardiol 2024;21:717\u201334. https:\/\/doi.org\/10.1038\/s41569-024-01046-6; PMID: 38926611. DOI: 10.1038\/s41569-024-01046-6","DOI":"10.1038\/s41569-024-01046-6"},{"key":"ref1","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 2024;403:1027\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(23)02750-2; PMID: 38432237."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Aryee EK, Ozkan B, Ndumele CE. Heart failure and obesity: the latest pandemic. Prog Cardiovasc Dis 2023;78:43\u20138. https:\/\/doi.org\/10.1016\/j.pcad.2023.05.003; PMID: 37236574. DOI: 10.1016\/j.pcad.2023.05.003","DOI":"10.1016\/j.pcad.2023.05.003"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Beghini A, Sammartino AM, Papp Z, et al. 2024 update in heart failure. ESC Heart Fail 2025;12:8\u201342. https:\/\/doi.org\/10.1002\/ehf2.14857; PMID: 38806171. DOI: 10.1002\/ehf2.14857","DOI":"10.1002\/ehf2.14857"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305\u201313. https:\/\/doi.org\/10.1056\/NEJMoa020245; PMID: 12151467. DOI: 10.1056\/NEJMoa020245","DOI":"10.1056\/NEJMoa020245"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Savji N, Meijers WC, Bartz TM, et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC Heart Fail 2018;6:701\u20139. https:\/\/doi.org\/10.1016\/j.jchf.2018.05.018; PMID: 30007554. DOI: 10.1016\/j.jchf.2018.05.018","DOI":"10.1016\/j.jchf.2018.05.018"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Benn M, Marott SCW, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Obesity increases heart failure incidence and mortality: observational and Mendelian randomization studies totalling over 1 million individuals. Cardiovasc Res 2023;118:3576\u201385. https:\/\/doi.org\/10.1093\/cvr\/cvab368; PMID: 34954789. DOI: 10.1093\/cvr\/cvab368","DOI":"10.1093\/cvr\/cvab368"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Pocock SJ, McMurray JJV, Dobson J, et al. Weight loss and mortality risk in patients with chronic heart failure in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008;29:2641\u201350. https:\/\/doi.org\/10.1093\/eurheartj\/ehn420; PMID: 18819960. DOI: 10.1093\/eurheartj\/ehn420","DOI":"10.1093\/eurheartj\/ehn420"},{"key":"ref8","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129\u2013200. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128; PMID: 27206819."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Vest AR, Chan M, Deswal A, et al. Nutrition, obesity, and cachexia in patients with heart failure: a consensus statement from the Heart Failure Society of America scientific statements committee. J Card Fail 2019;25:380\u2013400. https:\/\/doi.org\/10.1016\/j.cardfail.2019.03.007; PMID: 30877038. DOI: 10.1016\/j.cardfail.2019.03.007","DOI":"10.1016\/j.cardfail.2019.03.007"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Borlaug BA, Jensen MD, Kitzman DW, et al. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023;118:3434\u201350. https:\/\/doi.org\/10.1093\/cvr\/cvac120; PMID: 35880317. DOI: 10.1093\/cvr\/cvac120","DOI":"10.1093\/cvr\/cvac120"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Alpert MA, Terry BE, Mulekar M, et al. Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. Am J Cardiol 1997;80:736\u201340. https:\/\/doi.org\/10.1016\/s0002-9149(97)00505-5; PMID: 9315579. DOI: 10.1016\/S0002-9149(97)00505-5","DOI":"10.1016\/S0002-9149(97)00505-5"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Ramani GV, McCloskey C, Ramanathan RC, Mathier MA. Safety and efficacy of bariatric surgery in morbidly obese patients with severe systolic heart failure. Clin Cardiol 2008;31:516\u201320. https:\/\/doi.org\/10.1002\/clc.20315; PMID: 19006115. DOI: 10.1002\/clc.20315","DOI":"10.1002\/clc.20315"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Kydd A, Pugh PJ. Perils of weight loss: the advantage of being obese in patients with heart failure. Expert Rev Cardiovasc Ther 2009;7:263\u20137. https:\/\/doi.org\/10.1586\/14779072.7.3.263; PMID: 19296763. DOI: 10.1586\/14779072.7.3.263","DOI":"10.1586\/14779072.7.3.263"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Zamora E, D\u00edez-L\u00f3pez C, Lup\u00f3n J, et al. Weight loss in obese patients with heart failure. J Am Heart Assoc 2016;5:e002468. https:\/\/doi.org\/10.1161\/JAHA.115.002468; PMID: 27013541. DOI: 10.1161\/JAHA.115.002468","DOI":"10.1161\/JAHA.115.002468"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Rayner JJ, Peterzan MA, Clarke WT, et al. Obesity modifies the energetic phenotype of dilated cardiomyopathy. Eur Heart J 2021;43:868\u201377. https:\/\/doi.org\/10.1093\/eurheartj\/ehab663; PMID: 34542592. DOI: 10.1093\/eurheartj\/ehab663","DOI":"10.1093\/eurheartj\/ehab663"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol 2023;81:1810\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2023.01.049; PMID: 37137592. DOI: 10.1016\/j.jacc.2023.01.049","DOI":"10.1016\/j.jacc.2023.01.049"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Savarese G, Schiattarella GG, Lindberg F, et al. Heart failure and obesity: translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC. Eur J Heart Fail 2025;27:1273\u201393. https:\/\/doi.org\/10.1002\/ejhf.3676; PMID: 40328668. DOI: 10.1002\/ejhf.3676","DOI":"10.1002\/ejhf.3676"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Karakasis P, Fragakis N, Patoulias D, et al. The emerging role of glucagon-like peptide-1 receptor agonists in the management of obesity-related heart failure with preserved ejection fraction: benefits beyond what scales can measure? Biomedicines 2024;12:2112. https:\/\/doi.org\/10.3390\/biomedicines12092112; PMID: 39335625. DOI: 10.3390\/biomedicines12092112","DOI":"10.3390\/biomedicines12092112"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Wong CY, O\u2019Moore-Sullivan T, Leano R, et al. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 2004;110:3081\u20137. https:\/\/doi.org\/10.1161\/01.CIR.0000147184.13872.0F; PMID: 15520317. DOI: 10.1161\/01.CIR.0000147184.13872.0F","DOI":"10.1161\/01.CIR.0000147184.13872.0F"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Turkbey EB, McClelland RL, Kronmal RA, et al. The impact of obesity on the left ventricle: the Multi-Ethnic Study of Atherosclerosis (MESA). JACC Cardiovasc Imaging 2010;3:266\u201374. https:\/\/doi.org\/10.1016\/j.jcmg.2009.10.012; PMID: 20223423. DOI: 10.1016\/j.jcmg.2009.10.012","DOI":"10.1016\/j.jcmg.2009.10.012"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Mandry D, Girerd N, Lamiral Z, et al. Arterial and cardiac remodeling associated with extra weight gain in an isolated abdominal obesity cohort. Front Cardiovasc Med 2021;8:771022. https:\/\/doi.org\/10.3389\/fcvm.2021.771022; PMID: 34805324. DOI: 10.3389\/fcvm.2021.771022","DOI":"10.3389\/fcvm.2021.771022"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Zoccali C, Levin A, Mallamaci F, et al. Advanced chronic kidney disease coexisting with heart failure: navigating patients\u2019 management. Clin Kidney J 2025;18:sfaf128. https:\/\/doi.org\/10.1093\/ckj\/sfaf128; PMID: 40395996. DOI: 10.1093\/ckj\/sfaf128","DOI":"10.1093\/ckj\/sfaf128"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Jurica J, P\u00e9\u010d MJ, Benko J, et al. Obesity as a risk factor in atrial fibrillation and heart failure. J Diabetes Metab Disord 2024;23:125\u201334. https:\/\/doi.org\/10.1007\/s40200-023-01332-z; PMID: 38932866. DOI: 10.1007\/s40200-023-01332-z","DOI":"10.1007\/s40200-023-01332-z"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Xue B, Yu Y, Zhang Z, et al. Leptin mediates high-fat diet sensitization of angiotensin II\u2013elicited hypertension by upregulating the brain renin\u2013angiotensin system and inflammation. Hypertension 2016;67:970\u20136. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.115.06736; PMID: 27021010. DOI: 10.1161\/HYPERTENSIONAHA.115.06736","DOI":"10.1161\/HYPERTENSIONAHA.115.06736"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Deng L, Tighiouart H, Oka T, et al. Association of obesity with kidney function outcomes in heart failure with preserved ejection fraction. medRxiv 2025;2025.05.19.25327963. https:\/\/doi.org\/10.1101\/2025.05.19.25327963; PMID: 40475138; preprint. DOI: 10.1101\/2025.05.19.25327963","DOI":"10.1101\/2025.05.19.25327963"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Taegtmeyer H, Golfman L, Sharma S, et al. Linking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann N Y Acad Sci 2004;1015:202\u201313. https:\/\/doi.org\/10.1196\/annals.1302.017; PMID: 15201161. DOI: 10.1196\/annals.1302.017","DOI":"10.1196\/annals.1302.017"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Peterson LR, Herrero P, Schechtman KB, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004;109:2191\u20136. https:\/\/doi.org\/10.1161\/01.CIR.0000127959.28627.F8; PMID: 15123530. DOI: 10.1161\/01.CIR.0000127959.28627.F8","DOI":"10.1161\/01.CIR.0000127959.28627.F8"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Rider OJ, Francis JM, Ali MK, et al. Effects of catecholamine stress on diastolic function and myocardial energetics in obesity. Circulation 2012;125:1511\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.069518; PMID: 22368152. DOI: 10.1161\/CIRCULATIONAHA.111.069518","DOI":"10.1161\/CIRCULATIONAHA.111.069518"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000;97:1784\u20139. https:\/\/doi.org\/10.1073\/pnas.97.4.1784; PMID: 10677535. DOI: 10.1073\/pnas.97.4.1784","DOI":"10.1073\/pnas.97.4.1784"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the vesnarinone trial (VEST). Circulation 2001;103:2055\u20139. https:\/\/doi.org\/10.1161\/01.cir.103.16.2055; PMID: 11319194. DOI: 10.1161\/01.CIR.103.16.2055","DOI":"10.1161\/01.CIR.103.16.2055"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Bond RM, Ivy K, Crumbs T, et al. Coronary microvascular dysfunction and its role in heart failure with preserved ejection fraction for future prevention and treatment. Am J Prev Cardiol 2025;22:100983. https:\/\/doi.org\/10.1016\/j.ajpc.2025.100983; PMID: 40242363. DOI: 10.1016\/j.ajpc.2025.100983","DOI":"10.1016\/j.ajpc.2025.100983"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Janssen-Telders C, Eringa EC, de Groot JR, et al. The role of epicardial adipose tissue remodelling in heart failure with preserved ejection fraction. Cardiovasc Res 2025;121:860\u201370. https:\/\/doi.org\/10.1093\/cvr\/cvaf056; PMID: 40238568. DOI: 10.1093\/cvr\/cvaf056","DOI":"10.1093\/cvr\/cvaf056"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Paulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263\u201371. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.092; PMID: 23684677. DOI: 10.1016\/j.jacc.2013.02.092","DOI":"10.1016\/j.jacc.2013.02.092"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Canepa M, Anastasia G, Ameri P, et al. Characterization of ischemic etiology in heart failure with reduced ejection fraction randomized clinical trials: a systematic review and meta-analysis. Eur J Intern Med 2025;134:51\u20138. https:\/\/doi.org\/10.1016\/j.ejim.2025.02.004; PMID: 39939263. DOI: 10.1016\/j.ejim.2025.02.004","DOI":"10.1016\/j.ejim.2025.02.004"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Oreopoulos A, Padwal R, Kalantar-Zadeh K, et al. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J 2008;156:13\u201322. https:\/\/doi.org\/10.1016\/j.ahj.2008.02.014; PMID: 18585492. DOI: 10.1016\/j.ahj.2008.02.014","DOI":"10.1016\/j.ahj.2008.02.014"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Kapoor JR, Heidenreich PA. Obesity and survival in patients with heart failure and preserved systolic function: a U-shaped relationship. Am Heart J 2010;159:75\u201380. https:\/\/doi.org\/10.1016\/j.ahj.2009.10.026; PMID: 20102870. DOI: 10.1016\/j.ahj.2009.10.026","DOI":"10.1016\/j.ahj.2009.10.026"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Padwal R, McAlister FA, McMurray JJV, et al. The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. Int J Obes (Lond) 2014;38:1110\u20134. https:\/\/doi.org\/10.1038\/ijo.2013.203; PMID: 24173404. DOI: 10.1038\/ijo.2013.203","DOI":"10.1038\/ijo.2013.203"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Fonarow GC, Srikanthan P, Costanzo MR, et al. An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry. Am Heart J 2007;153:74\u201381. https:\/\/doi.org\/10.1016\/j.ahj.2006.09.007; PMID: 17174642. DOI: 10.1016\/j.ahj.2006.09.007","DOI":"10.1016\/j.ahj.2006.09.007"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Elbaz-Greener G, Rozen G, Carasso S, et al. The relationship between body mass index and in-hospital survival in patients admitted with acute heart failure. Front Cardiovasc Med 2022;9:855525. https:\/\/doi.org\/10.3389\/fcvm.2022.855525; PMID: 35571201. DOI: 10.3389\/fcvm.2022.855525","DOI":"10.3389\/fcvm.2022.855525"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Prokopidis K, Irlik K, Hendel M, et al. Prognostic impact and prevalence of cachexia in patients with heart failure: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2024;15:2536\u201343. https:\/\/doi.org\/10.1002\/jcsm.13596; PMID: 39478303. DOI: 10.1002\/jcsm.13596","DOI":"10.1002\/jcsm.13596"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Sharma A, Lavie CJ, Borer JS, et al. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol 2015;115:1428\u201334. https:\/\/doi.org\/10.1016\/j.amjcard.2015.02.024; PMID: 25772740. DOI: 10.1016\/j.amjcard.2015.02.024","DOI":"10.1016\/j.amjcard.2015.02.024"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Lavie CJ, Sharma A, Alpert MA, et al. Update on obesity and obesity paradox in heart failure. Prog Cardiovasc Dis 2016;58:393\u2013400. https:\/\/doi.org\/10.1016\/j.pcad.2015.12.003; PMID: 26721180. DOI: 10.1016\/j.pcad.2015.12.003","DOI":"10.1016\/j.pcad.2015.12.003"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Lavie CJ, Osman AF, Milani RV, Mehra MR. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol 2003;91:891\u20134. https:\/\/doi.org\/10.1016\/s0002-9149(03)00031-6; PMID: 12667583. DOI: 10.1016\/S0002-9149(03)00031-6","DOI":"10.1016\/S0002-9149(03)00031-6"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Tsujimoto T, Kajio H. Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF. J Am Coll Cardiol 2017;70:2739\u201349. https:\/\/doi.org\/10.1016\/j.jacc.2017.09.1111; PMID: 29191321. DOI: 10.1016\/j.jacc.2017.09.1111","DOI":"10.1016\/j.jacc.2017.09.1111"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Clark AL, Fonarow GC, Horwich TB. Waist circumference, body mass index, and survival in systolic heart failure: the obesity paradox revisited. J Card Fail 2011;17:374\u201380. https:\/\/doi.org\/10.1016\/j.cardfail.2011.01.009; PMID: 21549293. DOI: 10.1016\/j.cardfail.2011.01.009","DOI":"10.1016\/j.cardfail.2011.01.009"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Butt JH, Petrie MC, Jhund PS, et al. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. Eur Heart J 2023;44:1136\u201353. https:\/\/doi.org\/10.1093\/eurheartj\/ehad083; PMID: 36944496. DOI: 10.1093\/eurheartj\/ehad083","DOI":"10.1093\/eurheartj\/ehad083"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Reddy YNV, Anantha-Narayanan M, Obokata M, et al. Hemodynamic effects of weight loss in obesity: a systematic review and meta-analysis. JACC Heart Fail 2019;7:678\u201387. https:\/\/doi.org\/10.1016\/j.jchf.2019.04.019; https:\/\/doi.org\/S2213-1779(19)30334-8. PMID: 31302042. DOI: 10.1016\/j.jchf.2019.04.019","DOI":"10.1016\/j.jchf.2019.04.019"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Haufe S, Utz W, Engeli S, et al. Left ventricular mass and function with reduced-fat or reduced-carbohydrate hypocaloric diets in overweight and obese subjects. Hypertension 2012;59:70\u20135. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.178616; PMID: 22068866. DOI: 10.1161\/HYPERTENSIONAHA.111.178616","DOI":"10.1161\/HYPERTENSIONAHA.111.178616"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Rider OJ, Francis JM, Tyler D, et al. Effects of weight loss on myocardial energetics and diastolic function in obesity. Int J Cardiovasc Imaging 2013;29:1043\u201350. https:\/\/doi.org\/10.1007\/s10554-012-0174-6; PMID: 23269470. DOI: 10.1007\/s10554-012-0174-6","DOI":"10.1007\/s10554-012-0174-6"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Kitzman DW, Brubaker P, Morgan T, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2016;315:36\u201346. https:\/\/doi.org\/10.1001\/jama.2015.17346; PMID: 26746456. DOI: 10.1001\/jama.2015.17346","DOI":"10.1001\/jama.2015.17346"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"El Hajj EC, El Hajj MC, Sykes B, et al. Pragmatic weight management program for patients with obesity and heart failure with preserved ejection fraction. J Am Heart Assoc 2021;10:e022930. https:\/\/doi.org\/10.1161\/JAHA.121.022930; PMID: 34713711. DOI: 10.1161\/JAHA.121.022930","DOI":"10.1161\/JAHA.121.022930"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Mariotti R, Castrogiovanni F, Canale ML, et al. Weight loss and quality of life in chronic heart failure patients. J Cardiovasc Med (Hagerstown) 2008;9:576\u201380. https:\/\/doi.org\/10.2459\/JCM.0b013e3282f2de13; PMID: 18475125. DOI: 10.2459\/JCM.0b013e3282f2de13","DOI":"10.2459\/JCM.0b013e3282f2de13"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"van Veldhuisen SL, Gorter TM, van Woerden G, et al. Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J 2022;43:1955\u201369. https:\/\/doi.org\/10.1093\/eurheartj\/ehac071; PMID: 35243488. DOI: 10.1093\/eurheartj\/ehac071","DOI":"10.1093\/eurheartj\/ehac071"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Sundstr\u00f6m J, Bruze G, Ottosson J, et al. Weight loss and heart failure: a nationwide study of gastric bypass surgery versus intensive lifestyle treatment. Circulation 2017;135:1577\u201385. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.025629; PMID: 28258170. DOI: 10.1161\/CIRCULATIONAHA.116.025629","DOI":"10.1161\/CIRCULATIONAHA.116.025629"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Sorimachi H, Obokata M, Omote K, et al. Long-term changes in cardiac structure and function following bariatric surgery. J Am Coll Cardiol 2022;80:1501\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2022.08.738; PMID: 36229085. DOI: 10.1016\/j.jacc.2022.08.738","DOI":"10.1016\/j.jacc.2022.08.738"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Di Bello V, Santini F, Di Cori A, et al. Effects of bariatric surgery on early myocardial alterations in adult severely obese subjects. Cardiology 2008;109:241\u20138. https:\/\/doi.org\/10.1159\/000107787; PMID: 17873488. DOI: 10.1159\/000107787","DOI":"10.1159\/000107787"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Mikhalkova D, Holman SR, Jiang H, et al. Bariatric surgery-induced cardiac and lipidomic changes in obesity-related heart failure with preserved ejection fraction. Obesity (Silver Spring) 2018;26:284\u201390. https:\/\/doi.org\/10.1002\/oby.22038; PMID: 29243396. DOI: 10.1002\/oby.22038","DOI":"10.1002\/oby.22038"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Vest AR, Patel P, Schauer PR, et al. Clinical and echocardiographic outcomes after bariatric surgery in obese patients with left ventricular systolic dysfunction. Circ Heart Fail 2016;9:e002260. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.115.002260; PMID: 26945045. DOI: 10.1161\/CIRCHEARTFAILURE.115.002260","DOI":"10.1161\/CIRCHEARTFAILURE.115.002260"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Shimada YJ, Tsugawa Y, Brown DFM, Hasegawa K. Bariatric surgery and emergency department visits and hospitalizations for heart failure exacerbation: population-based, self-controlled series. J Am Coll Cardiol 2016;67:895\u2013903. https:\/\/doi.org\/10.1016\/j.jacc.2015.12.016; PMID: 26916477. DOI: 10.1016\/j.jacc.2015.12.016","DOI":"10.1016\/j.jacc.2015.12.016"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Aleassa EM, Khorgami Z, Kindel TL, et al. Impact of bariatric surgery on heart failure mortality. Surg Obes Relat Dis 2019;15:1189\u201396. https:\/\/doi.org\/10.1016\/j.soard.2019.03.021; PMID: 31147281. DOI: 10.1016\/j.soard.2019.03.021","DOI":"10.1016\/j.soard.2019.03.021"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Nesti L, Trico D. Cardioprotective effects of glucagon-like peptide 1 receptor agonists in heart failure: myth or truth? World J Diabetes 2024;15:818\u201322. https:\/\/doi.org\/10.4239\/wjd.v15.i5.818; PMID: 38766425. DOI: 10.4239\/wjd.v15.i5.818","DOI":"10.4239\/wjd.v15.i5.818"},{"key":"ref62","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2306963; PMID: 37622681."},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563; PMID: 37952131. DOI: 10.1056\/NEJMoa2307563","DOI":"10.1056\/NEJMoa2307563"},{"key":"ref64","unstructured":"Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet 2024;404:773\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(24)01498-3; PMID: 39181597."},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Hashmi TM, Ahmed M, Haider A, et al. Once-weekly semaglutide versus once-daily liraglutide for weight loss in adults: a meta-analysis of randomized controlled trials. Clin Transl Sci 2025;18:e70127. https:\/\/doi.org\/10.1111\/cts.70127; PMID: 39930946. DOI: 10.1111\/cts.70127","DOI":"10.1111\/cts.70127"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Borlaug BA, Zile MR, Kramer CM, et al. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat Med 2025;31:544\u201351. https:\/\/doi.org\/10.1038\/s41591-024-03374-z; PMID: 39551891. DOI: 10.1038\/s41591-024-03374-z","DOI":"10.1038\/s41591-024-03374-z"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Kramer CM, Borlaug BA, Zile MR, et al. Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy. J Am Coll Cardiol 2025;85:699\u2013706. https:\/\/doi.org\/10.1016\/j.jacc.2024.11.001; PMID: 39566869. DOI: 10.1016\/j.jacc.2024.11.001","DOI":"10.1016\/j.jacc.2024.11.001"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017;19:69\u201377. https:\/\/doi.org\/10.1002\/ejhf.657; PMID: 27790809. DOI: 10.1002\/ejhf.657","DOI":"10.1002\/ejhf.657"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Lepore JJ, Olson E, Demopoulos L, et al. Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC Heart Fail 2016;4:559\u201366. https:\/\/doi.org\/10.1016\/j.jchf.2016.01.008; PMID: 27039125. DOI: 10.1016\/j.jchf.2016.01.008","DOI":"10.1016\/j.jchf.2016.01.008"},{"key":"ref70","unstructured":"Marx N, Federici M, Sch\u00fctt K, et al. ESC Guidelines for the management of cardiovascular disease in patients with diabetes: developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J 2023;44:4043\u2013140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192; PMID: 37622663."},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab 2024;26(Suppl 4):16\u201327. https:\/\/doi.org\/10.1111\/dom.15728; PMID: 38937282. DOI: 10.1111\/dom.15728","DOI":"10.1111\/dom.15728"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Ilonze OJ, Forman DE, LeMond L, et al. Beyond guideline-directed medical therapy: nonpharmacologic management for patients with heart failure. JACC Heart Fail 2025;13:185\u201399. https:\/\/doi.org\/10.1016\/j.jchf.2024.08.018; PMID: 39453358. DOI: 10.1016\/j.jchf.2024.08.018","DOI":"10.1016\/j.jchf.2024.08.018"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Lee VYJ, Houston L, Perkovic A, et al. The effect of weight loss through lifestyle interventions in patients with heart failure with preserved ejection fraction \u2013 a systematic review and meta-analysis of randomised controlled trials. Heart Lung Circ 2024;33:197\u2013208. https:\/\/doi.org\/10.1016\/j.hlc.2023.11.022; PMID: 38320881. DOI: 10.1016\/j.hlc.2023.11.022","DOI":"10.1016\/j.hlc.2023.11.022"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Fukuta H, Goto T, Wakami K, et al. Effects of exercise training on cardiac function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Heart Fail Rev 2019;24:535\u201347. https:\/\/doi.org\/10.1007\/s10741-019-09774-5; PMID: 31032533. DOI: 10.1007\/s10741-019-09774-5","DOI":"10.1007\/s10741-019-09774-5"},{"key":"ref75","unstructured":"O\u2019Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301:1439\u201350. https:\/\/doi.org\/10.1001\/jama.2009.454; PMID: 19351941."},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Brubaker PH, Nicklas BJ, Houston DK, et al. A randomized, controlled trial of resistance training added to caloric restriction plus aerobic exercise training in obese heart failure with preserved ejection fraction. Circ Heart Fail 2023;16:e010161. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.122.010161; PMID: 36314122. DOI: 10.1161\/CIRCHEARTFAILURE.123.010419","DOI":"10.1161\/CIRCHEARTFAILURE.123.010419"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Kitzman DW, Whellan DJ, Duncan P, et al. Physical rehabilitation for older patients hospitalized for heart failure. N Engl J Med 2021;385:203\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2026141; PMID: 33999544. DOI: 10.1056\/NEJMoa2026141","DOI":"10.1056\/NEJMoa2026141"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Mousavi A, Shojaei S, Soleimani H, et al. Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr 2025;17:68. https:\/\/doi.org\/10.1186\/s13098-025-01635-6; PMID: 39994802. DOI: 10.1186\/s13098-025-01635-6","DOI":"10.1186\/s13098-025-01635-6"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Butler J, Fioretti F, Davies MJ. Redefining obesity: beyond body mass index. Eur Heart J 2025;46:3758\u201361. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf409; PMID: 40574617. DOI: 10.1093\/eurheartj\/ehaf409","DOI":"10.1093\/eurheartj\/ehaf409"}],"container-title":["European Cardiology Review"],"original-title":[],"link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2025.37","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T12:23:54Z","timestamp":1766492634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2025.37"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":80,"URL":"https:\/\/doi.org\/10.15420\/ecr.2025.37","relation":{},"ISSN":["1758-3756","1758-3764"],"issn-type":[{"value":"1758-3756","type":"print"},{"value":"1758-3764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"article-number":"e38"}}